Should you buy curis (Cris) stock on Hammer charts?
Apr 10, 2022 · Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug …
Who owns curis stock?
May 02, 2022 · CRIS | Complete Curis Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Where can I buy shares of Cris?
May 04, 2022 · Real-time trade and investing ideas on Curis Inc CRIS from the largest community of traders and investors.
What is the target price for curis?
May 04, 2022 · A high-level overview of Curis, Inc. (CRIS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Is Curis a buy right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 5 buy ratings for the stock. T...
How has Curis' stock price been impacted by Coronavirus?
Curis' stock was trading at $1.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since th...
When is Curis' next earnings date?
Curis is scheduled to release its next quarterly earnings announcement on Wednesday, May 11th 2022. View our earnings forecast for Curis .
How were Curis' earnings last quarter?
Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings results on Thursday, February, 24th. The biotechnology company reported ($0.15) earnings...
When did Curis' stock split? How did Curis' stock split work?
Curis shares reverse split on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned b...
What price target have analysts set for CRIS?
5 Wall Street analysts have issued 12 month price targets for Curis' shares. Their forecasts range from $12.00 to $22.00. On average, they anticipa...
Who are Curis' key executives?
Curis' management team includes the following people: James E. Dentzer , President, Chief Executive Officer & Director ( LinkedIn Profile ) Will...
Who are some of Curis' key competitors?
Some companies that are related to Curis include Amgen (AMGN) , Regeneron Pharmaceuticals (REGN) , Gilead Sciences (GILD) , Vertex Pharmaceutic...
What other stocks do shareholders of Curis own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD) , Celldex Ther...
About Curis
Curis (NASDAQ:CRIS) Frequently Asked Questions
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes.
Recently Viewed Tickers
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Curis stock. View analyst ratings for Curis or view top-rated stocks.
Curis Inc
Visit a quote page and your recently viewed tickers will be displayed here.
Should I Avoid Curis, Inc. (CRIS)?
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes.
Is the Options Market Predicting a Spike in Curis (CRIS) Stock?
Is Curis, Inc. (NASDAQ:CRIS) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]
How Many Curis, Inc. (NASDAQ:CRIS) Shares Do Institutions Own?
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.
Curis (CRIS) Moves to Buy: Rationale Behind the Upgrade
If you want to know who really controls Curis, Inc. ( NASDAQ:CRIS ), then you'll have to look at the makeup of its...
Here's Why Curis (CRIS) Could be Great Choice for a Bottom Fisher
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Curis (CRIS) Q3 2021 Earnings Call Transcript
Curis (CRIS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
Image source: The Motley Fool. Curis (NASDAQ: CRIS)Q3 2021 Earnings CallNov 09, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to Curis' third quarter 2021 earnings call.
Nasdaq Global Market
Curis (CRIS) delivered earnings and revenue surprises of 7.69% and 14.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Environmental, Social, and Governance Rating
A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Signals & Forecast
A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.
Support, Risk & Stop-loss
There are mixed signals in the stock today. The Curis stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Curis stock A Buy?
Curis finds support from accumulated volume at $3.15 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very negative
Curis holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
About Curis
In the last 1 trades there were . The last trade was done 19 047 days ago by who bough 0 shares.
Golden Star Signal
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for advanced lymphomas and multiple myeloma.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Curis, Inc. - Sell
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Style Scorecard
Zacks' proprietary data indicates that Curis, Inc. is currently rated as a Zacks Rank 4 and we are expecting a below average return from the CRIS shares relative to the market in the next few months. In addition, Curis, Inc.
Chart for CRIS
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
